This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Boston Scientific’s planned $14.5 billion acquisition of Penumbra started off the year with a bang. The two fast-growing, cardiovascular companies complement each other, with Boston Scientific seeing an opportunity to enter new markets, and Penumbra expecting its devices to gain a wider global reach. Boston Scientific CEO Mike Mahoney explained how they reached a de ...